Change in effectiveness of mammography screening with decreasing breast cancer mortality : a population-based study

Christiansen, Søren R. and Autier, Philippe and Støvring, Henrik (2022) Change in effectiveness of mammography screening with decreasing breast cancer mortality : a population-based study. European Journal of Public Health, 32 (4). pp. 630-635. ISSN 1101-1262 (https://doi.org/10.1093/eurpub/ckac047)

[thumbnail of Christiansen-etal-EJPH-2022-Change-in-effectiveness-of-mammography-screening]
Preview
 Text. Filename: Christiansen_etal_EJPH_2022_Change_in_effectiveness_of_mammography_screening.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (366kB)| Preview

Abstract

Background: Reductions in breast cancer mortality observed over the last three decades are partly due to improved patient management, which may erode the benefit-harm balance of mammography screening. Methods: We estimated the numbers of women needed to invite (NNI) to prevent one breast cancer death within 10 years. Four scenarios of screening effectiveness (5–20% mortality reduction) were applied on 10,580 breast cancer deaths among Norwegian women aged 50–75 years from 1986 to 2016. We used three scenarios of overdiagnosis (10–40% excess breast cancers during screening period) for estimating ratios of numbers of overdiagnosed breast cancers for each breast cancer death prevented. Results: Under the base case scenario of 20% breast cancer mortality reduction and 20% overdiagnosis, the NNI rose from 731 (95% CI: 644–830) women in 1996 to 1364 (95% CI: 1181–1577) women in 2016, while the number of women with overdiagnosed cancer for each breast cancer death prevented rose from 3.2 in 1996 to 5.4 in 2016. For a mortality reduction of 8.7%, the ratio of overdiagnosed breast cancers per breast cancer death prevented rose from 7.4 in 1996 to 14.0 in 2016. For a mortality reduction of 5%, the ratio rose from 12.8 in 1996 to 25.2 in 2016. Conclusions: Due to increasingly potent therapeutic modalities, the benefit in terms of reduced breast cancer mortality declines while the harms, including overdiagnosis, are unaffected. Future improvements in breast cancer patient management will further deteriorate the benefit–harm ratio of screening.

CORE (COnnecting REpositories)